Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | CES1 | P23141 | 2/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24832884 | 0.83 | CES2 (0.35) | CES2CES1BCHEALBGAA | |
| SCHEMBL25665104 | 0.83 | CES2 (0.35) | CES2CES1BCHEALBGAA | |
| SCHEMBL25626771 | 0.81 | CES2 (0.34) | CES2CES1BCHEALBGAA | |
| SCHEMBL17030746 | 0.81 | CES2 (0.42) | CES2CES1BCHEALBGAA | |
| SCHEMBL10222518 | 0.76 | ALB (0.55) | CES2CES1BCHEALBGAA | |
| SCHEMBL79047 | 0.75 | ACHE (0.39) | CES2CES1BCHEGAAMAPT | |
| SCHEMBL21891955 | 0.74 | CES2 (0.42) | CES2CES1BCHEALBGAA | |
| SCHEMBL22872664 | 0.73 | CES2 (0.52) | CES2CES1BCHEGAAMAPT | |
| SCHEMBL22023672 | 0.71 | GAA (0.62) | CES2CES1BCHEALBGAA | |
| SCHEMBL279180 | 0.70 | CYP3A4 (0.39) | CES2CES1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (US) | 2018-07-03 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247376-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | CES2 4559/4885CES1 2445/4885BCHE 2695/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CES2 4845/4885CES1 3347/4885BCHE 3787/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | CES2 4879/4885CES1 3492/4885BCHE 4052/4885 |
| US-10011600-B2 | Methods and compositions for inhibition of Ras | KRAS, NRAS, HRAS | CES2 4559/4885CES1 2445/4885BCHE 2695/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | CES2 4739/4885CES1 4071/4885BCHE 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.